ArticleCureus2022
Analysis of Neurological Adverse Events Reported in VigiBase From COVID-19 Vaccines.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- Potential association of cluster headache with certain COVID-19 vaccines: An assessment from the pharmacovigilance databases.Headache · 2026Article
- Glucocorticoid withdrawal syndrome: Disproportionality analysis of cases using VigiBase data.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2025Article
- Characteristics of Oral Adverse Effects following COVID-19 Vaccination and Similarities with Oral Symptoms in COVID-19 Patients: Taste and Saliva Secretory Disorders.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2025Review
- Network analysis of adverse event patterns following immunization with mRNA COVID-19 vaccines: real-world data from the European pharmacovigilance database EudraVigilance.Frontiers in medicine · 2025Article
- The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury.Advances in virology · 2025Review
- Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023.Scientific reports · 2024Article
- A Systematic Analysis of COVID-19 Clinical Trials Registered in the Clinical Trials Registry of India.Cureus · 2024Article
- Self-reported side effects of COVID-19 vaccines among health professions students in India.PeerJ · 2024Article
- Increased frequency and intensity of complicated migraine sans migraine after third BNT162b2 dose.Clinics (Sao Paulo, Brazil) · 2024Article
- Review of adverse events associated with COVID-19 vaccines, highlighting their frequencies and reported cases.Journal of Taibah University Medical Sciences · 2023Review
- The Serum ACE2, CTSL, AngII, and TNFα Levels after COVID-19 and mRNA Vaccines: The Molecular Basis.Biomedicines · 2023Article
- Neurological Adverse Reactions to SARS-CoV-2 Vaccines.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2023Review
- Review
- A review of neurological side effects of COVID-19 vaccination.European journal of medical research · 2023Review
- Review
- A retrospective analysis of clinically confirmed long post-COVID vaccination syndrome.Journal of clinical and translational research · 2022Article
- Review
- A Case Report: Long Post-COVID Vaccination Syndrome During the Eleven Months After the Third Moderna Dose.Cureus · 2022Article
- Dystonia as a complication of COVID-19 vaccinations is not as rare as portrayed.Clinical neurology and neurosurgery · 2022Article
- Development of facial palsy following COVID-19 vaccination: A systematic review.Annals of medicine and surgery (2012) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFifteen COVID-19 vaccines have been granted emergency approval before the completion of conventional phases of clinical trials. The present study aimed to analyze the neurological adverse events (AEs) post-COVID-19 vaccination and focuses on determining the association of AEs with the vaccine. METHODOLOGY: The neurological AEs reported for COVID-19 vaccines in the WHO pharmacovigilance database (VigiBase) were extracted from the System Organ Classes - neurological disorders and investigations. Descriptive statistics are reported as percentage and frequency and the disproportionality analysis was also conducted.
resultsFor the neurological system, 19,529 AEs were reported. Of these, 15,638 events were reported from BNT162b2 vaccine, 2,751 from AZD1222 vaccine, 1,075 from mRNA-1273 vaccine, eight from Vero vaccine, two from Covaxin, and for 55 AEs, vaccine name was not mentioned. The reason for more AEs reported with BNT162b2 can be maximum vaccination with BNT162b2 vaccine in the study period. According to the disproportionality analysis based on IC
conclusionThe vaccines should be monitored for these AEs till the causality of these AEs with COVID-19 vaccines is established through further long-term follow-up studies. These neurological AEs reported in VigiBase should not be taken as conclusive and mass vaccination should be carried out to control the pandemic until a definite link of these adverse effects is established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.